BioMarin Pharmaceutical reported quarterly EPS of $0.76, missing the $0.94 Zacks Consensus Estimate by $0.18 per share, or about 19%. Earnings also declined from $1.13 per share a year ago, signaling weaker year-over-year profitability. The print is a modest negative for the stock and likely to move shares, but it is not a major sector event.
BioMarin Pharmaceutical reported quarterly EPS of $0.76, missing the $0.94 Zacks Consensus Estimate by $0.18 per share, or about 19%. Earnings also declined from $1.13 per share a year ago, signaling weaker year-over-year profitability. The print is a modest negative for the stock and likely to move shares, but it is not a major sector event.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.34
Ticker Sentiment
